Just Released: "Orphan Drugs: Rescue from the Patent Cliff"
Orphan drugs treat diseases that affect fewer than 1 in 2,000 Europeans & fewer than 200,000 Americans. Research into orphan drugs benefits from incentives provided by the 1983 Orphan Drug Act, such as tax breaks, faster regulatory reviews and assistance from FDA reviewers. Orphan drugs are less likely to face competition and provide a high return on investment. Cinryze costs $487,000 annually.